Nanjing Vcare Assists Nanjing Chiatai Tianqing in Obtaining Lenvatinib Production License

2021-11-18

Recently, Nanjing Chiatai Tianqing Pharmaceutical Co., Ltd. has obtained a drug registration certificate for "Mesylate Lenvatinib Capsules" issued by the National Drug Administration, which is a chemical drug of category 4, and this approval is deemed to have passed the quality and efficacy consistency evaluation. The mesylate lenvatinib capsules approved this time are another classic case of the full-chain R&D service provided by Nanjing Vcare PharmaTechCo., Ltd. The Nanjing Vcare and Nanjing Chiatai Tianqing teams worked closely together and made every effort to accelerate the research and development, completing the key starting materials, raw materials, and capsule development and ANDA registration work in 20 months, and completing the supplementary research work in 2 months. They obtained the production license on the third try, achieving a breakthrough. This project is another important cooperative progress with Nanjing Chiatai Tianqing after the August 1st clinical permission for the AKT targeted inhibitor 1st-class new drug.

 

Lenvatinib capsules are an oral, selective receptor tyrosine kinase inhibitor (TKI) that can act on both tumor cell VEGFR-1 and VEGFR-3, FGFR1-4, PDGFR-b, KIT, and RET at the same time, thereby affecting angiogenesis and tumor proliferation. It can be used for the treatment of kidney cancer, liver cancer, etc. Lenvatinib capsules are a targeted small molecule anti-cancer drug that was approved by the FDA in 2015. Prior to this, it had not been approved in China. With the approval of domestic lenvatinib, we believe that both the accessibility of the drug and its clinical performance will bring good news to patients with kidney cancer and liver cancer.

Prev

Nanjing Vcare Assists Hualon Pharmaceutical in Passing the Conformity Evaluation for Omeprazole Sodium and Pantoprazole Sodium

Next

Nanjing Vcare Helps Shanghai Institute of Materia Medica's Anti-cancer Drug LH-1802 Gain Approval for Clinical Research